BC Cancer - Vancouver

600 W 10th Avenue
Vancouver, BC V5Z 4E6

Clinical Trial Unit Manager
Darko Curman
604-877-6000 x673226
dcurman@bccancer.bc.ca

Breast

IND.236: A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination With Weekly Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy

Cancer Type
Breast
Not Applicable
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Phase III, Multicenter, Randomized Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab Paclitaxel Compared With Placebo With Nab Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A phase IIIb, single-arm, open-label multicentre study of olaparib monotherapy in the treatment of HER2-ve metastatic breast cancer patients with germline BRCA1/2 mutations

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal women with estrogen receptor-positive advanced breast cancer

Cancer Type
Breast
Phase I/II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

CARA: Multicentre Randomized Controlled Trial Of A Carbon-Fibre Adjustable Reusable Accessory For Supine Breast Positioning To Reduce Toxicity In Whole Breast Adjuvant Radiotherapy

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
BC Cancer - Surrey
Open Recruiting Date
BC Cancer - Prince George (Centre for the North)
Open Recruiting Date
View on ClinicalTrials.gov

Treat ER+ight: Treatment of Canadian Postmenopausal Women with ER+ Advanced Breast Cancer in the Real-World Setting with Hormone Therapy ± Targeted Therapy

Cancer Type
Breast
Not Applicable
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Victoria
Open Recruiting Date
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
Open Recruiting Date
BC Cancer - Prince George (Centre for the North)
Open Recruiting Date
BC Cancer - Surrey
Open Recruiting Date
BC Cancer - Vancouver
Open Recruiting Date
BC Cancer - Abbotsford
Open Recruiting Date
View on ClinicalTrials.gov

MAC.25: A Randomized, Double-Blind, Phase III Trial of Paclitaxel / Trastuzumab / Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Victoria
Open Recruiting Date
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

LA LEAST: Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A Trial of Abbreviated Hormone Therapy for Low Risk Hormone Receptor Positive, HER2 Negative Early Breast Cancer

FINER: A Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
BC Cancer - Surrey
Open Recruiting Date
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
View on ClinicalTrials.gov

KEYNOTE-756: A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer 

DESTINY 6: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Phase 2 Study of VLS-101 in Patients with Solid Tumors

A randomized, multicenter, double-blind, phase III study of AZD9833 (an oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the treatment of patients with estrogen receptor-positive, HER2-negative advanced breast cancer who have not received any systemic treatment for advanced disease

Back to top